Riser Pharmaceuticals-B Surges 25% to HKD 25 on July 2 Amid Commercialization of Lead Product Weizhen High

According to Smart Finance, Riser Pharmaceuticals-B (02561) climbed 25.13% to close at HKD 25 on July 2, with intraday gains reaching nearly 30%, leading Hong Kong's biotech sector.

The rally follows the January 2026 regulatory approval of the company's lead product, Weizhen High (lonapegsomatropin), a long-acting growth hormone indicated for children and adolescents with growth hormone deficiency. The product requires once-weekly subcutaneous injection and demonstrated superior efficacy versus daily-injected growth hormone in both the global heiGHt and Chinese briGHt Phase 3 trials. Commercial rollout is progressing through partnerships with public hospitals via Ansci Biologics and private medical institutions including Concord Medical Services.